Grøntvedt's Vertical Integration Targets Longevity Market with New Omega-11 Lipid Production

Oslo, Norway — 19 May 2026

Grøntvedt Biotech, a spin-off from Norway's established pelagic fishing enterprise, Grøntvedt Group, is strategically pivoting towards advanced lipid production for the longevity supplement market. The company, historically focused on harvesting and processing herring and mackerel, is leveraging its deep-rooted marine operations to establish a vertically integrated supply chain for novel omega fatty acids, specifically omega-11.

This initiative represents a significant commercial play by Grøntvedt to move beyond commoditised bulk fish oil into high-value, functionally targeted ingredients. The company aims to differentiate its offerings by developing precision lipids that address specific health endpoints such as cardiovascular health, skin wellness, and overall healthspan, as highlighted in new research surrounding omega-11's potential.

Their prior successful launch of a sustainable, cetoleic acid-rich Norwegian Herring fish oil, processed from 'fish to oil in 30 minutes', underscores their capability for rapid, high-purity ingredient extraction. This efficiency in processing minimises oxidation and preserves nutrient integrity, a critical factor for premium supplement formulations. The move into omega-11 production indicates a strategic intent to dominate the innovation end of the marine oil sector.

Investment in scientific research and consumer awareness for omega-11 is anticipated, mirroring the trajectory of omega-3. This suggests a long-term commitment to establishing omega-11 as a recognised and sought-after ingredient within the health and longevity space, competing with established omega-3 and emerging alternative lipid sources.

What this means for United Kingdom

UK supplement brand owners must evaluate their ingredient portfolios against this developing trend. The emergence of high-purity, sustainably sourced omega-11 could offer a strong differentiation point in the competitive UK longevity market. Procurement teams should monitor Grøntvedt's supply chain scale-up and projected delivery windows, which are expected to stabilise by late 2026, to assess potential cost-performance advantages over existing omega-3 sources. Regulatory compliance for novel food ingredients will be a critical consideration, requiring engagement with the Food Standards Agency (FSA). Early engagement with Grøntvedt or their distributors could secure favourable MOQs and pricing, while delaying could result in higher costs as market demand grows.

The company's history in sustainable marine practices and rapid processing provides a strong narrative for UK brands seeking clean-label, traceable ingredients. This vertical integration strategy could potentially reduce lead times and supply chain vulnerabilities compared to multi-vendor sourcing models. Brand owners should prepare for new marketing claims that highlight omega-11's specific benefits, aligning with the growing consumer interest in tailored health solutions.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.